Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China

NCT01596855 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia in End Stage Renal Disease

Interventions

DRUG: FG-4592
DRUG: Epoetin Alfa

Sponsor

Kyntra Bio

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]